fibroblast like op9 feeder cells (ATCC)
ATCC is a verified supplier 
ATCC manufactures this product 
96
Structured Review
ATCC
fibroblast like op9 feeder cells
Fibroblast Like Op9 Feeder Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 415 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fibroblast+like+op9+feeder+cells/OP9/pm41850246-320-1-8
Average 96 stars, based on 415 article reviews
Fibroblast Like Op9 Feeder Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 415 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fibroblast+like+op9+feeder+cells/OP9/pm41850246-320-1-8
Average 96 stars, based on 415 article reviews
fibroblast like op9 feeder cells - by Bioz Stars,
2026-10
96/100 stars
Images
Related Articles
Cell Culture:Article Title: Inhibition of MAPK p38α overcomes the cancer immunosurveillance defect caused by FPR1 loss-of-function mutation. Article Snippet: Following staining, cells were washed twice with 200 μL FACS buffer, fixed in 1% PFA for 20 min, washed twice, and acquired by FACS within 24 h. Flow cytometric data acquisition was using a BD LSRFortessa flow cytometer (BD Biosciences) or CytoFLEX flow cytometer (Beckman Coulter) and analyzed with FlowJo software or the CytoExpert software. Article Title: Inhibition of MAPK p38α overcomes the cancer immunosurveillance defect caused by FPR1 loss-of-function mutation Article Snippet: The knockout or point mutation of Fpr1 in parental iniDCs were performed by co-transfecting the iniDCs with custom-designed sgRNA, single-strand DNA donor oligos (sequence listed in ), and an EGFP Cas9 nuclease mRNA (Cat# CAS12217 , Horizon Discovery), using the DharmaFECT Duo transfection reagent (Cat# T-2010-03, Horizon Discovery). Inhibition:Article Title: Inhibition of MAPK p38α overcomes the cancer immunosurveillance defect caused by FPR1 loss-of-function mutation. Article Snippet: Following staining, cells were washed twice with 200 μL FACS buffer, fixed in 1% PFA for 20 min, washed twice, and acquired by FACS within 24 h. Flow cytometric data acquisition was using a BD LSRFortessa flow cytometer (BD Biosciences) or CytoFLEX flow cytometer (Beckman Coulter) and analyzed with FlowJo software or the CytoExpert software. Article Title: Inhibition of MAPK p38α overcomes the cancer immunosurveillance defect caused by FPR1 loss-of-function mutation Article Snippet: The knockout or point mutation of Fpr1 in parental iniDCs were performed by co-transfecting the iniDCs with custom-designed sgRNA, single-strand DNA donor oligos (sequence listed in ), and an EGFP Cas9 nuclease mRNA (Cat# CAS12217 , Horizon Discovery), using the DharmaFECT Duo transfection reagent (Cat# T-2010-03, Horizon Discovery). Migration:Article Title: Inhibition of MAPK p38α overcomes the cancer immunosurveillance defect caused by FPR1 loss-of-function mutation. Article Snippet: Following staining, cells were washed twice with 200 μL FACS buffer, fixed in 1% PFA for 20 min, washed twice, and acquired by FACS within 24 h. Flow cytometric data acquisition was using a BD LSRFortessa flow cytometer (BD Biosciences) or CytoFLEX flow cytometer (Beckman Coulter) and analyzed with FlowJo software or the CytoExpert software. Article Title: Inhibition of MAPK p38α overcomes the cancer immunosurveillance defect caused by FPR1 loss-of-function mutation Article Snippet: The knockout or point mutation of Fpr1 in parental iniDCs were performed by co-transfecting the iniDCs with custom-designed sgRNA, single-strand DNA donor oligos (sequence listed in ), and an EGFP Cas9 nuclease mRNA (Cat# CAS12217 , Horizon Discovery), using the DharmaFECT Duo transfection reagent (Cat# T-2010-03, Horizon Discovery). Mutagenesis:Article Title: Inhibition of MAPK p38α overcomes the cancer immunosurveillance defect caused by FPR1 loss-of-function mutation. Article Snippet: Following staining, cells were washed twice with 200 μL FACS buffer, fixed in 1% PFA for 20 min, washed twice, and acquired by FACS within 24 h. Flow cytometric data acquisition was using a BD LSRFortessa flow cytometer (BD Biosciences) or CytoFLEX flow cytometer (Beckman Coulter) and analyzed with FlowJo software or the CytoExpert software. Article Title: Inhibition of MAPK p38α overcomes the cancer immunosurveillance defect caused by FPR1 loss-of-function mutation Article Snippet: The knockout or point mutation of Fpr1 in parental iniDCs were performed by co-transfecting the iniDCs with custom-designed sgRNA, single-strand DNA donor oligos (sequence listed in ), and an EGFP Cas9 nuclease mRNA (Cat# CAS12217 , Horizon Discovery), using the DharmaFECT Duo transfection reagent (Cat# T-2010-03, Horizon Discovery). In Vitro:Article Title: Inhibition of MAPK p38α overcomes the cancer immunosurveillance defect caused by FPR1 loss-of-function mutation. Article Snippet: Following staining, cells were washed twice with 200 μL FACS buffer, fixed in 1% PFA for 20 min, washed twice, and acquired by FACS within 24 h. Flow cytometric data acquisition was using a BD LSRFortessa flow cytometer (BD Biosciences) or CytoFLEX flow cytometer (Beckman Coulter) and analyzed with FlowJo software or the CytoExpert software. Article Title: Inhibition of MAPK p38α overcomes the cancer immunosurveillance defect caused by FPR1 loss-of-function mutation Article Snippet: The knockout or point mutation of Fpr1 in parental iniDCs were performed by co-transfecting the iniDCs with custom-designed sgRNA, single-strand DNA donor oligos (sequence listed in ), and an EGFP Cas9 nuclease mRNA (Cat# CAS12217 , Horizon Discovery), using the DharmaFECT Duo transfection reagent (Cat# T-2010-03, Horizon Discovery). In Vivo:Article Title: Inhibition of MAPK p38α overcomes the cancer immunosurveillance defect caused by FPR1 loss-of-function mutation. Article Snippet: Following staining, cells were washed twice with 200 μL FACS buffer, fixed in 1% PFA for 20 min, washed twice, and acquired by FACS within 24 h. Flow cytometric data acquisition was using a BD LSRFortessa flow cytometer (BD Biosciences) or CytoFLEX flow cytometer (Beckman Coulter) and analyzed with FlowJo software or the CytoExpert software. Article Title: Inhibition of MAPK p38α overcomes the cancer immunosurveillance defect caused by FPR1 loss-of-function mutation Article Snippet: The knockout or point mutation of Fpr1 in parental iniDCs were performed by co-transfecting the iniDCs with custom-designed sgRNA, single-strand DNA donor oligos (sequence listed in ), and an EGFP Cas9 nuclease mRNA (Cat# CAS12217 , Horizon Discovery), using the DharmaFECT Duo transfection reagent (Cat# T-2010-03, Horizon Discovery). Expressing:Article Title: Inhibition of MAPK p38α overcomes the cancer immunosurveillance defect caused by FPR1 loss-of-function mutation. Article Snippet: Following staining, cells were washed twice with 200 μL FACS buffer, fixed in 1% PFA for 20 min, washed twice, and acquired by FACS within 24 h. Flow cytometric data acquisition was using a BD LSRFortessa flow cytometer (BD Biosciences) or CytoFLEX flow cytometer (Beckman Coulter) and analyzed with FlowJo software or the CytoExpert software. Article Title: Inhibition of MAPK p38α overcomes the cancer immunosurveillance defect caused by FPR1 loss-of-function mutation Article Snippet: The knockout or point mutation of Fpr1 in parental iniDCs were performed by co-transfecting the iniDCs with custom-designed sgRNA, single-strand DNA donor oligos (sequence listed in ), and an EGFP Cas9 nuclease mRNA (Cat# CAS12217 , Horizon Discovery), using the DharmaFECT Duo transfection reagent (Cat# T-2010-03, Horizon Discovery). Staining:Article Title: Inhibition of MAPK p38α overcomes the cancer immunosurveillance defect caused by FPR1 loss-of-function mutation. Article Snippet: Following staining, cells were washed twice with 200 μL FACS buffer, fixed in 1% PFA for 20 min, washed twice, and acquired by FACS within 24 h. Flow cytometric data acquisition was using a BD LSRFortessa flow cytometer (BD Biosciences) or CytoFLEX flow cytometer (Beckman Coulter) and analyzed with FlowJo software or the CytoExpert software. Article Title: Inhibition of MAPK p38α overcomes the cancer immunosurveillance defect caused by FPR1 loss-of-function mutation Article Snippet: The knockout or point mutation of Fpr1 in parental iniDCs were performed by co-transfecting the iniDCs with custom-designed sgRNA, single-strand DNA donor oligos (sequence listed in ), and an EGFP Cas9 nuclease mRNA (Cat# CAS12217 , Horizon Discovery), using the DharmaFECT Duo transfection reagent (Cat# T-2010-03, Horizon Discovery). Imaging:Article Title: Inhibition of MAPK p38α overcomes the cancer immunosurveillance defect caused by FPR1 loss-of-function mutation. Article Snippet: Following staining, cells were washed twice with 200 μL FACS buffer, fixed in 1% PFA for 20 min, washed twice, and acquired by FACS within 24 h. Flow cytometric data acquisition was using a BD LSRFortessa flow cytometer (BD Biosciences) or CytoFLEX flow cytometer (Beckman Coulter) and analyzed with FlowJo software or the CytoExpert software. Article Title: Inhibition of MAPK p38α overcomes the cancer immunosurveillance defect caused by FPR1 loss-of-function mutation Article Snippet: The knockout or point mutation of Fpr1 in parental iniDCs were performed by co-transfecting the iniDCs with custom-designed sgRNA, single-strand DNA donor oligos (sequence listed in ), and an EGFP Cas9 nuclease mRNA (Cat# CAS12217 , Horizon Discovery), using the DharmaFECT Duo transfection reagent (Cat# T-2010-03, Horizon Discovery). Comparison:Article Title: Inhibition of MAPK p38α overcomes the cancer immunosurveillance defect caused by FPR1 loss-of-function mutation. Article Snippet: Following staining, cells were washed twice with 200 μL FACS buffer, fixed in 1% PFA for 20 min, washed twice, and acquired by FACS within 24 h. Flow cytometric data acquisition was using a BD LSRFortessa flow cytometer (BD Biosciences) or CytoFLEX flow cytometer (Beckman Coulter) and analyzed with FlowJo software or the CytoExpert software. Article Title: Inhibition of MAPK p38α overcomes the cancer immunosurveillance defect caused by FPR1 loss-of-function mutation Article Snippet: The knockout or point mutation of Fpr1 in parental iniDCs were performed by co-transfecting the iniDCs with custom-designed sgRNA, single-strand DNA donor oligos (sequence listed in ), and an EGFP Cas9 nuclease mRNA (Cat# CAS12217 , Horizon Discovery), using the DharmaFECT Duo transfection reagent (Cat# T-2010-03, Horizon Discovery). Labeling:Article Title: Inhibition of MAPK p38α overcomes the cancer immunosurveillance defect caused by FPR1 loss-of-function mutation. Article Snippet: Following staining, cells were washed twice with 200 μL FACS buffer, fixed in 1% PFA for 20 min, washed twice, and acquired by FACS within 24 h. Flow cytometric data acquisition was using a BD LSRFortessa flow cytometer (BD Biosciences) or CytoFLEX flow cytometer (Beckman Coulter) and analyzed with FlowJo software or the CytoExpert software. Article Title: Inhibition of MAPK p38α overcomes the cancer immunosurveillance defect caused by FPR1 loss-of-function mutation Article Snippet: The knockout or point mutation of Fpr1 in parental iniDCs were performed by co-transfecting the iniDCs with custom-designed sgRNA, single-strand DNA donor oligos (sequence listed in ), and an EGFP Cas9 nuclease mRNA (Cat# CAS12217 , Horizon Discovery), using the DharmaFECT Duo transfection reagent (Cat# T-2010-03, Horizon Discovery). Injection:Article Title: Inhibition of MAPK p38α overcomes the cancer immunosurveillance defect caused by FPR1 loss-of-function mutation. Article Snippet: Following staining, cells were washed twice with 200 μL FACS buffer, fixed in 1% PFA for 20 min, washed twice, and acquired by FACS within 24 h. Flow cytometric data acquisition was using a BD LSRFortessa flow cytometer (BD Biosciences) or CytoFLEX flow cytometer (Beckman Coulter) and analyzed with FlowJo software or the CytoExpert software. Article Title: Inhibition of MAPK p38α overcomes the cancer immunosurveillance defect caused by FPR1 loss-of-function mutation Article Snippet: The knockout or point mutation of Fpr1 in parental iniDCs were performed by co-transfecting the iniDCs with custom-designed sgRNA, single-strand DNA donor oligos (sequence listed in ), and an EGFP Cas9 nuclease mRNA (Cat# CAS12217 , Horizon Discovery), using the DharmaFECT Duo transfection reagent (Cat# T-2010-03, Horizon Discovery). Immunohistochemical staining:Article Title: Inhibition of MAPK p38α overcomes the cancer immunosurveillance defect caused by FPR1 loss-of-function mutation. Article Snippet: Following staining, cells were washed twice with 200 μL FACS buffer, fixed in 1% PFA for 20 min, washed twice, and acquired by FACS within 24 h. Flow cytometric data acquisition was using a BD LSRFortessa flow cytometer (BD Biosciences) or CytoFLEX flow cytometer (Beckman Coulter) and analyzed with FlowJo software or the CytoExpert software. Article Title: Inhibition of MAPK p38α overcomes the cancer immunosurveillance defect caused by FPR1 loss-of-function mutation Article Snippet: The knockout or point mutation of Fpr1 in parental iniDCs were performed by co-transfecting the iniDCs with custom-designed sgRNA, single-strand DNA donor oligos (sequence listed in ), and an EGFP Cas9 nuclease mRNA (Cat# CAS12217 , Horizon Discovery), using the DharmaFECT Duo transfection reagent (Cat# T-2010-03, Horizon Discovery). CRISPR:Article Title: Inhibition of MAPK p38α overcomes the cancer immunosurveillance defect caused by FPR1 loss-of-function mutation. Article Snippet: Following staining, cells were washed twice with 200 μL FACS buffer, fixed in 1% PFA for 20 min, washed twice, and acquired by FACS within 24 h. Flow cytometric data acquisition was using a BD LSRFortessa flow cytometer (BD Biosciences) or CytoFLEX flow cytometer (Beckman Coulter) and analyzed with FlowJo software or the CytoExpert software. Article Title: Inhibition of MAPK p38α overcomes the cancer immunosurveillance defect caused by FPR1 loss-of-function mutation Article Snippet: The knockout or point mutation of Fpr1 in parental iniDCs were performed by co-transfecting the iniDCs with custom-designed sgRNA, single-strand DNA donor oligos (sequence listed in ), and an EGFP Cas9 nuclease mRNA (Cat# CAS12217 , Horizon Discovery), using the DharmaFECT Duo transfection reagent (Cat# T-2010-03, Horizon Discovery). Immunohistochemistry:Article Title: Inhibition of MAPK p38α overcomes the cancer immunosurveillance defect caused by FPR1 loss-of-function mutation. Article Snippet: Following staining, cells were washed twice with 200 μL FACS buffer, fixed in 1% PFA for 20 min, washed twice, and acquired by FACS within 24 h. Flow cytometric data acquisition was using a BD LSRFortessa flow cytometer (BD Biosciences) or CytoFLEX flow cytometer (Beckman Coulter) and analyzed with FlowJo software or the CytoExpert software. Article Title: Inhibition of MAPK p38α overcomes the cancer immunosurveillance defect caused by FPR1 loss-of-function mutation Article Snippet: The knockout or point mutation of Fpr1 in parental iniDCs were performed by co-transfecting the iniDCs with custom-designed sgRNA, single-strand DNA donor oligos (sequence listed in ), and an EGFP Cas9 nuclease mRNA (Cat# CAS12217 , Horizon Discovery), using the DharmaFECT Duo transfection reagent (Cat# T-2010-03, Horizon Discovery). Single Cell:Article Title: Inhibition of MAPK p38α overcomes the cancer immunosurveillance defect caused by FPR1 loss-of-function mutation. Article Snippet: Following staining, cells were washed twice with 200 μL FACS buffer, fixed in 1% PFA for 20 min, washed twice, and acquired by FACS within 24 h. Flow cytometric data acquisition was using a BD LSRFortessa flow cytometer (BD Biosciences) or CytoFLEX flow cytometer (Beckman Coulter) and analyzed with FlowJo software or the CytoExpert software. Article Title: Inhibition of MAPK p38α overcomes the cancer immunosurveillance defect caused by FPR1 loss-of-function mutation Article Snippet: The knockout or point mutation of Fpr1 in parental iniDCs were performed by co-transfecting the iniDCs with custom-designed sgRNA, single-strand DNA donor oligos (sequence listed in ), and an EGFP Cas9 nuclease mRNA (Cat# CAS12217 , Horizon Discovery), using the DharmaFECT Duo transfection reagent (Cat# T-2010-03, Horizon Discovery). Flow Cytometry:Article Title: Inhibition of MAPK p38α overcomes the cancer immunosurveillance defect caused by FPR1 loss-of-function mutation. Article Snippet: Following staining, cells were washed twice with 200 μL FACS buffer, fixed in 1% PFA for 20 min, washed twice, and acquired by FACS within 24 h. Flow cytometric data acquisition was using a BD LSRFortessa flow cytometer (BD Biosciences) or CytoFLEX flow cytometer (Beckman Coulter) and analyzed with FlowJo software or the CytoExpert software. Article Title: Inhibition of MAPK p38α overcomes the cancer immunosurveillance defect caused by FPR1 loss-of-function mutation Article Snippet: The knockout or point mutation of Fpr1 in parental iniDCs were performed by co-transfecting the iniDCs with custom-designed sgRNA, single-strand DNA donor oligos (sequence listed in ), and an EGFP Cas9 nuclease mRNA (Cat# CAS12217 , Horizon Discovery), using the DharmaFECT Duo transfection reagent (Cat# T-2010-03, Horizon Discovery). Fluorescence:Article Title: Inhibition of MAPK p38α overcomes the cancer immunosurveillance defect caused by FPR1 loss-of-function mutation. Article Snippet: Following staining, cells were washed twice with 200 μL FACS buffer, fixed in 1% PFA for 20 min, washed twice, and acquired by FACS within 24 h. Flow cytometric data acquisition was using a BD LSRFortessa flow cytometer (BD Biosciences) or CytoFLEX flow cytometer (Beckman Coulter) and analyzed with FlowJo software or the CytoExpert software. Article Title: Inhibition of MAPK p38α overcomes the cancer immunosurveillance defect caused by FPR1 loss-of-function mutation Article Snippet: The knockout or point mutation of Fpr1 in parental iniDCs were performed by co-transfecting the iniDCs with custom-designed sgRNA, single-strand DNA donor oligos (sequence listed in ), and an EGFP Cas9 nuclease mRNA (Cat# CAS12217 , Horizon Discovery), using the DharmaFECT Duo transfection reagent (Cat# T-2010-03, Horizon Discovery). Variant Assay:Article Title: Inhibition of MAPK p38α overcomes the cancer immunosurveillance defect caused by FPR1 loss-of-function mutation. Article Snippet: Following staining, cells were washed twice with 200 μL FACS buffer, fixed in 1% PFA for 20 min, washed twice, and acquired by FACS within 24 h. Flow cytometric data acquisition was using a BD LSRFortessa flow cytometer (BD Biosciences) or CytoFLEX flow cytometer (Beckman Coulter) and analyzed with FlowJo software or the CytoExpert software. Article Title: Inhibition of MAPK p38α overcomes the cancer immunosurveillance defect caused by FPR1 loss-of-function mutation Article Snippet: The knockout or point mutation of Fpr1 in parental iniDCs were performed by co-transfecting the iniDCs with custom-designed sgRNA, single-strand DNA donor oligos (sequence listed in ), and an EGFP Cas9 nuclease mRNA (Cat# CAS12217 , Horizon Discovery), using the DharmaFECT Duo transfection reagent (Cat# T-2010-03, Horizon Discovery). Derivative Assay:Article Title: Inhibition of MAPK p38α overcomes the cancer immunosurveillance defect caused by FPR1 loss-of-function mutation. Article Snippet: Following staining, cells were washed twice with 200 μL FACS buffer, fixed in 1% PFA for 20 min, washed twice, and acquired by FACS within 24 h. Flow cytometric data acquisition was using a BD LSRFortessa flow cytometer (BD Biosciences) or CytoFLEX flow cytometer (Beckman Coulter) and analyzed with FlowJo software or the CytoExpert software. Article Title: Inhibition of MAPK p38α overcomes the cancer immunosurveillance defect caused by FPR1 loss-of-function mutation Article Snippet: The knockout or point mutation of Fpr1 in parental iniDCs were performed by co-transfecting the iniDCs with custom-designed sgRNA, single-strand DNA donor oligos (sequence listed in ), and an EGFP Cas9 nuclease mRNA (Cat# CAS12217 , Horizon Discovery), using the DharmaFECT Duo transfection reagent (Cat# T-2010-03, Horizon Discovery). Control:Article Title: Inhibition of MAPK p38α overcomes the cancer immunosurveillance defect caused by FPR1 loss-of-function mutation. Article Snippet: Following staining, cells were washed twice with 200 μL FACS buffer, fixed in 1% PFA for 20 min, washed twice, and acquired by FACS within 24 h. Flow cytometric data acquisition was using a BD LSRFortessa flow cytometer (BD Biosciences) or CytoFLEX flow cytometer (Beckman Coulter) and analyzed with FlowJo software or the CytoExpert software. Article Title: Inhibition of MAPK p38α overcomes the cancer immunosurveillance defect caused by FPR1 loss-of-function mutation Article Snippet: The knockout or point mutation of Fpr1 in parental iniDCs were performed by co-transfecting the iniDCs with custom-designed sgRNA, single-strand DNA donor oligos (sequence listed in ), and an EGFP Cas9 nuclease mRNA (Cat# CAS12217 , Horizon Discovery), using the DharmaFECT Duo transfection reagent (Cat# T-2010-03, Horizon Discovery). |